NCT04873141

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia: Experience From Single Center of Pakistan

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 24 (actual)
• Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.

Detailed description

This observational study was designed just to visualize the efficacy and safety of Tocilizumab, an antibody anti-IL-6 receptor in patients with moderate to severe COVID-19 with increased inflammatory markers.Patients will be followed until Day 29 after randomization.

Conditions

• Cytokine Release Syndrome
• Covid-19 Pneumonia

Interventions

Type	Name	Description
DRUG	Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)	Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).

Timeline

• Start date: 2020-04-28
• Primary completion: 2020-06-22
• Completion: 2020-06-22
• First posted: 2021-05-05
• Last updated: 2021-05-05

Locations

1 site across 1 country: Pakistan

Regulatory

• FDA-regulated drug study